Panelists discuss how; the patient case presents a 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC. The patient ...
Lung cancer is one of the leading causes of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about ...
Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...
EGFR-TKI 已成为 EGFR 突变晚期非小细胞肺癌（NSCLC）患者的标准治疗方案[1]，然而，约 2%~5% 的初治 EGFR 突变晚期 NSCLC 患者合并原发 MET 扩增，且接受 EGFR-TKI ...
SC amivantamab, in combination with LAZCLUZE, is recommended for adult patients with advanced NSCLC with epidermal growth ...
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...
EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...
从2022年7月19日至2024年4月12日，患者在接受一线治疗期间，连续进行CT复查，结果显示疾病稳定（SD），且无进展生存期（PFS）竟达21个月之久。这对于EGFR突变合并MET扩增的患者而言，显然是一个积极的信号。
Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...
As monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of platinum-based therapy.
南昌大学第一附属医院的科研团队在《Cell Death Discovery》期刊发表了题为 “GTPase GPN3 facilitates cell proliferation and migration in non - small cell lung cancer by impeding clathrin - mediated endocytosis of EGFR” 的研究 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback